A Network for Innovation: Excellos’ Partnership with Blood Centers of America
Strong partnerships are essential to delivering consistent, high-quality starting material for cell and gene therapy—and our collaboration with Blood Centers of America (BCA), through San Diego Blood Bank, is a great example of that impact in action.
Our Blood Centers of America Partnership Journey
Since 2020, Excellos has proudly been a member of BCA, a nationwide cooperative of independent, nonprofit blood centers that supports over 50% of the country’s transfusion needs. Their commitment to aligning standards across the U.S. has been instrumental in helping us access standardized donor material and reliably deliver high-quality products to our clients.
We’re grateful for this partnership and the continued collaboration that helps drive innovation across the CGT space.
Why This Partnership Matters:
- Access to standardized, high quality starting cellular materials: BCA’s Advanced Therapies Network enables the collection and processing of critical blood and cellular products used in research, clinical trials, and commercial manufacturing. The standardization of starting materials across all blood suppliers is critical for ensuring consistent quality, regulatory compliance, and reliability. Our close relationship with BCA gives us direct access to this starting material.
- Scalability: In addition to starting materials, this partnership allows us to work with a large wealth of vendors for all other materials. As the largest single network of facilities providing human, blood derived biologics in the world, BCA offers a footprint designed for CGT supply chain scale.
- Collaborative Innovation in Cell and Gene Therapy: One of the key benefits of working with BCA is the ability to support and scale decentralized manufacturing more effectively. Galapagos’s mission to advance decentralized manufacturing is strengthened through its partnership with BCA, whose extensive network of blood centers across diverse regions lays a strong foundation for this model. Excellos is proud to be the first decentralized manufacturing CDMO for Galapagos in the BCA Advanced Therapies Network, uniquely positioning us to advance their decentralized manufacturing goals. Together, we are not only enabling the launch of future decentralized units but also driving greater standardization and efficiency across the board.
Looking Forward
We’re proud to be a valued member of BCA and look forward to driving continued innovation and excellence in cell and gene therapy manufacturing. To learn more about how Excellos and BCA are advancing cell and gene therapy through innovation and collaboration, connect with our team today.
